Home
Leadership
Science
Data
Media
- News
- Videos
Partners
Contact

Listen to our founder and CEO, Lewis Gruber discuss SIWA and 318H!

02Apr 2021 by Andrew Premovich

Search for:

About Us

SIWA’s 318H monoclonal antibody targets a biomarker on cancer cells and senescent cells. Our initial focus is on life-threatening cancers and related diseases with an unmet medical need (i.e., eligible for FDA Fast-tracking)

Recent News

New antibody shows strong potential against pancreatic cancer
SIWA Therapeutics, Inc. Presents New Data at the November 2022 American Association for Cancer Research Aging and Cancer Conference
SIWA Therapeutics Announces Promising Results in New Pancreatic Cancer Study

Navigation

Home
Leadership
Science
Data
Media
- News
- Videos
Partners
Contact